We could not find any results for:
Make sure your spelling is correct or try broadening your search.
- IMC-2 treatment, dosed as valacyclovir 750 mg + celecoxib 200 mg twice daily, demonstrated clinically meaningful reduction in Long-COVID related fatigue and sleep disturbance as compared to...
- Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) formed in October by combination of Virios Therapeutics, Inc. and Pharmagesic (Holdings) Inc., 100% parent company of Wex Pharmaceuticals, Inc. (the...
ATLANTA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
ATLANTA, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), formerly Virios Therapeutics, Inc., a clinical‐stage biopharmaceutical company, announced...
Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron®...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.52 | -21.3991769547 | 2.43 | 2.44 | 1.88 | 23666 | 2.11893433 | CS |
4 | -0.4 | -17.316017316 | 2.31 | 2.9999 | 1.88 | 29214 | 2.51867708 | CS |
12 | -2.59 | -57.5555555556 | 4.5 | 5.15 | 1.62 | 46882 | 2.93173213 | CS |
26 | -1.64 | -46.1971830986 | 3.55 | 5.29 | 1.62 | 76401 | 3.46194376 | CS |
52 | -1.64 | -46.1971830986 | 3.55 | 5.29 | 1.62 | 76401 | 3.46194376 | CS |
156 | -1.64 | -46.1971830986 | 3.55 | 5.29 | 1.62 | 76401 | 3.46194376 | CS |
260 | -1.64 | -46.1971830986 | 3.55 | 5.29 | 1.62 | 76401 | 3.46194376 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions